Open Access
ISSN:0965-0407(print)
ISSN:1555-3906(online)
Publication Frequency:Monthly
Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of basic, translational, and clinical cancer research, with a particular interest in cancer therapeutics, providing a new platform for the understanding, prevention, diagnosis, and treatment of cancer.
Science Citation Index Expanded (Clarivate Analytics): 2023 Impact Factor: 2.0; Scopus CiteScore (Impact per Publication 2023): 4.4; SNIP (Source Normalized Impact per Paper 2023): 0.473; Embase; PubMed Central; MEDLINE; EBSCO; Google Scholar; Proquest; Portico, etc.
Open Access
REVIEW
Oncology Research, Vol.32, No.10, pp. 1543-1564, 2024, DOI:10.32604/or.2024.043987 - 18 September 2024
（This article belongs to the Special Issue: Advances in Cancer Immunotherapy)
Abstract The advent of RNA therapy, particularly through the development of mRNA cancer vaccines, has ushered in a new era in the field of oncology. This article provides a concise overview of the key principles, recent advancements, and potential implications of mRNA cancer vaccines as a groundbreaking modality in cancer treatment. mRNA cancer vaccines represent a revolutionary approach to combatting cancer by leveraging the body’s innate immune system. These vaccines are designed to deliver specific mRNA sequences encoding cancer-associated antigens, prompting the immune system to recognize and mount a targeted response against malignant cells. This personalized… More >
Graphic Abstract
Open Access
ARTICLE
Oncology Research, Vol.32, No.10, pp. 1565-1573, 2024, DOI:10.32604/or.2024.052179 - 18 September 2024
Abstract Objectives: The Brazilian Unified Health System (Sistema Único de Saúde−SUS) is the universal public healthcare system of Brazil that maintains a nationwide database of its patients. Our primary objective was to analyze regional and temporal trends, while our secondary goal was to establish correlations between states’ health economy status and their prostate cancer (PCa) epidemiology. Methods: We analyzed Brazil’s nationwide data on prostate cancer (PCa) incidence, mortality, and care gathered between 2013 and 2021 by the Information Technology Department of SUS (DATA-SUS), updated monthly using the International Classification of Diseases (ICD-10) code. Results: In the period,… More >
Open Access
ARTICLE
Oncology Research, Vol.32, No.10, pp. 1575-1587, 2024, DOI:10.32604/or.2024.047893 - 18 September 2024
Abstract Background: Immune checkpoint ligand-receptor interactions appear to be associated with multiple myeloma (MM) progression. Simultaneously, previous studies showed the possibility of PD-1 and TIM-3 expression on T cells upon stimulation with common γ-chain family cytokines in vitro and during homeostatic proliferation. The aim of the present work was to study the impact of homeostatic proliferation on the expansion of certain T cell subsets up-regulating PD-1 and TIM-3 checkpoint molecules. Methods: The expression of CD25, CD122, CD127 common γ-chain cytokine receptors, phosphorylated signal transducer and activator of transcription-5 (pSTAT5) and eomesodermin (EOMES) was comparatively assessed with flow… More >
Open Access
REVIEW
Oncology Research, Vol.32, No.10, pp. 1589-1612, 2024, DOI:10.32604/or.2024.052120 - 18 September 2024
Abstract Oral squamous cell carcinoma (OSCC) is one of the most prevalent forms of head and neck squamous cell carcinomas (HNSCC) with a poor overall survival rate (about 50%), particularly in cases of metastasis. RNA-based cancer biomarkers are a relatively advanced concept, and non-coding RNAs currently have shown promising roles in the detection and treatment of various malignancies. This review underlines the function of long non-coding RNAs (lncRNAs) in the OSCC and its subsequent clinical implications. LncRNAs, a class of non-coding RNAs, are larger than 200 nucleotides and resemble mRNA in numerous ways. However, unlike mRNA,… More >
Open Access
REVIEW
Oncology Research, Vol.32, No.10, pp. 1613-1621, 2024, DOI:10.32604/or.2024.047933 - 18 September 2024
（This article belongs to the Special Issue: Metabolism of Cancer Cells and Immune Cells: A Balancing Action for Cancer Immunotherapy)
Abstract Elevated serum cholesterol metabolism is associated with a reduced risk of lung cancer. Disrupted cholesterol metabolism is evident in both lung cancer patients and tumor cells. Inhibiting tumor cell cholesterol uptake or biosynthesis pathways, through the modulation of receptors and enzymes such as liver X receptor and sterol-regulatory element binding protein 2, effectively restrains lung tumor growth. Similarly, promoting cholesterol excretion yields comparable effects. Cholesterol metabolites, including oxysterols and isoprenoids, play a crucial role in regulating cholesterol metabolism within tumor cells, consequently impacting cancer progression. In lung cancer patients, both the cholesterol levels in the… More >
Open Access
ARTICLE
Oncology Research, Vol.32, No.10, pp. 1623-1635, 2024, DOI:10.32604/or.2024.048191 - 18 September 2024
Abstract Background: Oral cancer, a malignancy that is prevalent worldwide, is often diagnosed at an advanced stage. MicroRNAs (miRNAs) in circulating exosomes have emerged as promising cancer biomarkers. The role of miRNA let-7c-5p in oral cancer remains underexplored, and its potential involvement in tumorigenesis warrants comprehensive investigation. Methods: Serum samples from 30 patients with oral cancer and 20 healthy controls were used to isolate exosomes and quantify their RNA content. Isolation of the exosomes was confirmed through transmission electron microscopy. Quantitative PCR was used to assess the miRNA profiles. The effects of let-7c-5p and TAGLN overexpression… More >
Open Access
ARTICLE
Oncology Research, Vol.32, No.10, pp. 1637-1648, 2024, DOI:10.32604/or.2024.052664 - 18 September 2024
（This article belongs to the Special Issue: New Era in Cancer Treatment: Advances in Targeted and Pharmacological Therapies with the Subtle Integration of Multi-Omics)
Abstract Background: Metformin has pleiotropic effects beyond glucose reduction, including tumor inhibition and immune regulation. It enhanced the anti-tumor effects of programmed cell death protein 1 (PD-1) inhibitors in serine/threonine kinase 11 (STK11) mutant non-small cell lung cancer (NSCLC) through an axis inhibition protein 1 (AXIN1)-dependent manner. However, the alterations of tumor metabolism and metabolites upon metformin administration remain unclear. Methods: We performed untargeted metabolomics using liquid chromatography (LC)-mass spectrometry (MS)/MS system and conducted cell experiments to verify the results of bioinformatics analysis. Results: According to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database, most… More >
Graphic Abstract
Open Access
REVIEW
Oncology Research, Vol.32, No.10, pp. 1649-1660, 2024, DOI:10.32604/or.2024.043482 - 18 September 2024
Abstract Exosomes, minute vesicles ubiquitously released by diverse cell types, serve as critical mediators in intercellular communication. Their pathophysiological relevance, especially in malignancies, has garnered significant attention. A meticulous exploration of the exosomal impact on cancer development has unveiled avenues for innovative and clinically valuable techniques. The cargo conveyed by exosomes exerts transformative effects on both local and distant microenvironments, thereby influencing a broad spectrum of biological responses in recipient cells. These membrane-bound extracellular vesicles (EVs) play a pivotal role in delivering bioactive molecules among cells and organs. Cellular and biological processes in recipient cells, ranging… More >
Graphic Abstract
Open Access
REVIEW
Oncology Research, Vol.32, No.10, pp. 1661-1671, 2024, DOI:10.32604/or.2024.048287 - 18 September 2024
Abstract Glutamine is one of the most abundant non-essential amino acids in human plasma and plays a crucial role in many biological processes of the human body. Tumor cells take up a large amount of glutamine to meet their rapid proliferation requirements, which is supported by the upregulation of glutamine transporters. Targeted inhibition of glutamine transporters effectively inhibits cell growth and proliferation in tumors. Among all cancers, digestive system malignant tumors (DSMTs) have the highest incidence and mortality rates, and the current therapeutic strategies for DSMTs are mainly surgical resection and chemotherapy. Due to the relatively More >
Graphic Abstract
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1673-1674, 2024, DOI:10.32604/or.2024.056900 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1675-1676, 2024, DOI:10.32604/or.2024.056889 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1677-1678, 2024, DOI:10.32604/or.2024.056891 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1679-1680, 2024, DOI:10.32604/or.2024.056894 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1681-1682, 2024, DOI:10.32604/or.2024.056898 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1683-1684, 2024, DOI:10.32604/or.2024.056899 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1685-1686, 2024, DOI:10.32604/or.2024.056901 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1687-1688, 2024, DOI:10.32604/or.2024.056903 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1689-1690, 2024, DOI:10.32604/or.2024.056905 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1691-1692, 2024, DOI:10.32604/or.2024.056908 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1693-1694, 2024, DOI:10.32604/or.2024.056909 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1695-1696, 2024, DOI:10.32604/or.2024.056913 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1697-1698, 2024, DOI:10.32604/or.2024.056918 - 18 September 2024
Abstract This article has no abstract. More >
Open Access
RETRACTION
Oncology Research, Vol.32, No.10, pp. 1699-1700, 2024, DOI:10.32604/or.2024.056919 - 18 September 2024
Abstract This article has no abstract. More >
Login
Register
Submit a Paper
Propose a Special lssue
